FDA Modeling and AI in Generic Drug Development 2025: AI and Quantitative Medicine – Q&A Panel скачать в хорошем качестве

FDA Modeling and AI in Generic Drug Development 2025: AI and Quantitative Medicine – Q&A Panel

SUBSCRIBE to ⁨@FDALearningCache⁩ to see more videos. Details and supporting materials: https://fdalearn.com/course/fda-crcg-... About: Quantitative Medicine has long guided drug development by transforming biology into models, predictions, and decisions. Whether through pharmacometrics, systems pharmacology, or translational modeling, it has helped reduce uncertainty and increase precision across the drug lifecycle. Today, a new force is accelerating this transformation: Artificial Intelligence/Machine Learning. More than a buzzword, AI/ML approaches are becoming an indispensable extension of Quantitative Medicine—augmenting our ability to analyze massive, complex datasets, generate real-time insights, and simulate decisions at scale. In this session, we explore how AI is unlocking new possibilities for the entire lifecycle of drug development. Moderator: Joga Gobburu, PhD, MBA Professor, SOP and SOM, UMB; Co-Founder, Vivpro Corp Panelists: Andrew Babiskin, PhD Lead Pharmacokineticist, DQMM, ORS, OGD, FDA Vladmir Chupakhin, PhD Principal Scientist, Simulation Plus Inc. Qi Liu, PhD, MStat, FCP Associate Director for Innovation & Partnership, OCP, OTS, FDA Bhagwant Rege, PhD Division Director for Biopharmaceutics, OPQA I, OPQ, FDA Adarsh Subbaswamy, PhD Assistant Professor, Center for Translational Medicine, UMB SOP Ross Walenga, PhD Senior Chemical Engineer, DQMM, ORS, OGD, FDA Zhen Zhang, PhD Master Pharmacologist, DB I, OB, OGD, FDA Liang Zhao, PhD, MAS, MBA Professor & VC, Dept Bioengineering & Therapeutic Sci, SOP & SOM UCSF